At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,057 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR) Formulation 11mg Once Daily (QD) and Tofacitinib Immediate Release (IR) Formulation 5 mg Twice Daily (BID) Within a United States (US) Healthcare Claims Database
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 1,057 participants across 1 site.
Detailed Summary
The purpose of this study is to compare adherence, persistence, and effectiveness among patients initiating tofacitinib Modified Release (MR) with tofacitinib Immediate Release (IR).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
Primary CompletionApr 2019
First PostedJul 2019
TodayJul 2026
First PostedJul 12, 2019
Enrollment StartApr 12, 2019
Primary CompletionApr 25, 2019
TodayJul 2, 2026
Enrollment to primary: 13 daysPosted 7.0 years ago